While ERT can be life-saving, it also comes with challenges. Neonates have underdeveloped organs and immune systems, making them more susceptible to adverse reactions. Ensuring the appropriate dosage and managing potential immune responses are critical. Additionally, the high cost of enzyme replacement therapies can be a significant barrier, requiring consideration of long-term healthcare planning and support.
